Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

FLUPHENAZINE (ORAL) vs OLANZAPINE

Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of PANSS score < 40%, decreased rate of BPRS score < 40% · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.33 [0.86, 2.07]
1 study · 60 participants
Very low

FLUPHENAZINE (ORAL) vs OLANZAPINE

Relapse ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs OLANZAPINE

Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs OLANZAPINE

Quality of life (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs OLANZAPINE

Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up… compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3 [0.9, 10.01]
1 study · 60 participants
Very low

FLUPHENAZINE (ORAL) vs OLANZAPINE

Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3 [0.33, 27.23]
1 study · 60 participants
Very low

FLUPHENAZINE (ORAL) vs OLANZAPINE

Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found